Navigation Links
New Ovarian Cancer Drug Trial Under Way
Date:9/7/2007

Phenoxodiol could help women resistant to other medicines

FRIDAY, Sept. 7 (HealthDay News) -- Ovarian cancer patients whose cancer has become resistant to traditional chemotherapy can now log-on to a new Web site to learn about a trial of a new drug, phenoxodiol.

In previous studies, phenoxodiol has shown some success in helping traditional chemotherapies continue to fight cancer cells.

The Phase III study of phenoxodiol will take place at 30 sites in the United States, 26 sites in Europe and at least four sites in Australia.

The goal of the Web site, www.OVATUREtrial.com, is to inform ovarian cancer patients about the Ovarian Tumor Response (OVATURE) trial, which is actively recruiting patients. Women suffering with ovarian cancer can learn about the study, the medication and locations for them to participate.

The trial is studying the safety and effectiveness of the drug phenoxodiol when combined with weekly doses of the chemotherapy drug carboplatin. Phenoxodiol is believed to help chemotherapy drugs kill chemoresistant cancer cells by removing factors in the cells that block the killing action of chemotherapy. Phenoxodiol has not yet been approved for use by the U.S. Food and Drug Administration.

Women who enter the trial will be assigned to one of two courses of treatment. The first will receive weekly carboplatin and phenoxodiol. Patients in the other course will receive carboplatin and a placebo weekly. Patients and their doctors will not know which course of treatment they have been given.

Receiving carboplatin weekly instead of every two or three weeks has been shown to provide tumor response in some patients with recurrent ovarian cancer. The study will expand understanding of the safety and effectiveness of both phenoxodiol and weekly carboplatin.

Phenoxodiol has been shown to reverse resistance to standard chemotherapies in lab animals. In a prior Phase II clinical trial, the drug showed some success in reversing tumor progression when it was tested in combination with cisplatin or paclitaxel.

Ovarian cancer occurs in one out of every 69 women and is the fifth leading cause of cancer death in women, according to the Ovarian Cancer National Alliance. It can be treated if diagnosed early, but most ovarian cancers are caught at later stages. When diagnosed in an advanced stage, women have a 30 percent chance of surviving five years.

More information

To learn more about ovarian cancer, visit the Ovarian Cancer National Alliance.



-- Madeline Vann



SOURCE: OVATURE, press release, Aug. 30, 2007


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Ovarian cancer in relationship with Hormone therapy
2. Progestin protects against ovarian cancer
3. Inherited gene important in ovarian cancer
4. Blood test may identify ovarian cancer
5. Exercise lowers Risk of Ovarian Cancer
6. Screening device for ovarian cancer
7. Ethnic discrepancy in ovarian cancer
8. Associated scan for detecting ovarian cancer spread
9. Gene Mutation Causes Ovarian Failure
10. Ovarian Cancer Screening Questioned
11. Thawed Ovarian Transplant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2016)... ... ... "Color Grading media can be time consuming but with FCPX LUT Night ... Austin - CEO of Pixel Film Studios. , With the FCPX LUT Night ... to their footage. A LUT is a Lookup Table that contains a mathematical formula ...
(Date:5/27/2016)... CA (PRWEB) , ... May 27, 2016 , ... More ... Health, so it is not surprising that bariatric surgery has received increased attention in ... Journal explains. Of course, when it comes to weight loss, most people are familiar ...
(Date:5/27/2016)... ... May 27, 2016 , ... An influential resource amongst nurses and ... to shed lights on the variety of topics detailing why we appreciate nurses in ... why this career has gone from being in a major recession to one of ...
(Date:5/27/2016)... ... May 27, 2016 , ... ... educate the many who are unaware of the plight of aphasia. In collaboration ... within the “Stroke Awareness” campaign. , The link between stroke and aphasia is ...
(Date:5/27/2016)... ... May 27, 2016 , ... Each year Standard ... Allison Outerbridge is this year’s Life University winner of a $2,500 ... university’s Student Leadership Awards ceremony. , Outerbridge is approaching her last quarter at ...
Breaking Medicine News(10 mins):
(Date:5/26/2016)... May 26, 2016 Since its ... into an essential life science tool for conducting genetic ... BCC Research reveals in its new report that the ... phase, one powered by a range of new applications ...      (Logo: http://photos.prnewswire.com/prnh/20140723/694805 ) , ...
(Date:5/25/2016)... GERMANTOWN, Maryland , May 25, 2016 /PRNewswire/ ... Frankfurt Prime Standard: QIA) today announced that the company has ... GmbH to develop and commercialize predictive assays in oncology. An ... a marker to predict effectiveness of anthracycline treatment in triple ... are pleased to partner with Therawis, which developed the PITX2 ...
(Date:5/25/2016)... 2016 As illustrated by the ... month, the numbers and momentum of cannabis in the ... the billions, more research and development push the sector ... of Legal Marijuana Markets Report  from from ArcView Market ... of the increase in sector is attributed to adult ...
Breaking Medicine Technology: